Close Menu

NEW YORK – Roche announced this week that its Elecsys Growth Differentiation Factor-15 (GDF-15) test received breakthrough device designation from the US Food and Drug Administration as a companion diagnostic in cancer treatment. The quantitative serologic immunoassay measures GDF-15 in patients with solid tumors for treatment with Pfizer’s investigational drug PF-069446860. Elevated GDF-15 levels can indicate cachexia in cancer patients, a complication of cancer associated with involuntary weight loss, muscle atrophy, and reduced appetite that can also lead to death.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.